Stereotactic Focal Radiotherapy as an Alternative Treatment to Active Surveillance for Low and Intermediate Risk Prostate Cancer

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE ·

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to treat certain early-stage prostate cancers using a special type of targeted radiation called stereotactic focal radiotherapy. Instead of watching the cancer closely without treatment (called active surveillance), this approach aims to treat just the visible tumor area with precise radiation. The goal is to see if this focused treatment can lower the chance that patients will need more aggressive treatments later, while also reducing side effects and anxiety that can come from simply waiting and watching.

Men who might be eligible for this study have early-stage prostate cancer with a low to intermediate risk score (CAPRA score of 5 or less), no serious urinary problems, and are otherwise good candidates for active surveillance. The trial will compare two groups: one receiving this focused radiation treatment and the other continuing with active surveillance. If you join, you won’t need anesthesia for the radiation, and the doctors will monitor you closely to see which approach works better at avoiding additional treatments. This study is not yet open for enrollment but is designed to help find safer, less invasive options for men with certain prostate cancers.

Gender

MALE

Eligibility criteria